8.835USD-3.50%Mkt Cap: 82.59M USDP/E: —Last update: 2026-06-01
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prul…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap82.59M USD
Enterprise Value-36.66M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-116.80M USD
Revenue/Share—
Last Price8.835 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees102
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0070021086
Valuation
P/E (Trailing)—
P/E (Forward)-2.22
PEG—
EV/EBITDA0.34
EV/Revenue—
P/S—
P/B0.64
EPS (TTM)-13.87
EPS (Forward)-4.19
52W Range
6.01025% of range17.44
52W High17.44 USD
52W Low6.010 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.36%
ROA-60.72%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-95.25M USD
CapEx (TTM)1.74M USD
FCF Margin—
FCF Yield-58.73%
Net Debt-123.69M USD
Net Debt/EBITDA1.15
Balance Sheet
Debt/Equity0.09
Current Ratio7.66
Quick Ratio7.52
Book Value/Sh14.59 USD
Cash/Share14.72 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 16, 2020
Splits
Last Split1:16
Split DateDec 30, 2025
Analyst Consensus
Rating—
Target (Mean)34.83 USD
Target Range18.00 USD – 100.00 USD
# Analysts6
Ownership
Shares Out.9.35M
Float5.83M
Insiders0.92%
Institutions63.57%
Short Interest
Short Ratio5.2d
Short % Float6.31%
Short % Out.6.29%
Shares Short587.84K
Short (prev mo.)598.46K
Technical
SMA 507.575 (+16.6%)
SMA 2009.499 (-7.0%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)99.55K
Avg Vol (10d)122.31K
Technical Indicators
RSI (14)65.3
MACD0.2340
MACD Signal0.1493
MACD Hist.+0.0847
BB Upper9.103 USD
BB Middle8.212 USD
BB Lower7.321 USD
BB Width21.70%
ATR (14)0.5346 USD
Vol Ratio (20d)1.39x